Citalopram and escitalopram are closely related antidepressants, but they are not identical. Escitalopram is essentially the purified active half of citalopram, isolated from a 50/50 mixture of two mirror-image molecules. This distinction sounds small on paper, but it has real consequences for dosing, how quickly people respond, and how the two drugs compare in clinical trials. Both belong to the same drug class, both are widely prescribed, and both are now available as inexpensive generics, which makes the choice between them a genuinely practical question for millions of people.
The Mirror-Image Chemistry
Many drug molecules exist in two forms that are structurally identical but spatially reversed, like a left hand and a right hand. Citalopram contains equal parts of both forms: the S-enantiomer (the “left hand”) and the R-enantiomer (the “right hand”). Only the S-enantiomer has a strong affinity for the serotonin transporter, which is the protein these drugs block to raise serotonin levels in the brain.1PubMed. Escitalopram and citalopram: the unexpected role of the R-enantiomer Escitalopram is that S-enantiomer on its own, stripped of its inactive partner.
So when you take citalopram, roughly half of the drug in your bloodstream is doing the therapeutic work and the other half is mostly along for the ride. Escitalopram removes that inactive half, which is why a 10 mg dose of escitalopram delivers about the same amount of active ingredient as a 20 mg dose of citalopram. The R-enantiomer isn’t entirely inert, though. Early laboratory work suggested it might interfere with the S-enantiomer’s ability to bind to the serotonin transporter, potentially slowing down citalopram’s effects. Later research using human versions of the serotonin transporter found no evidence that R-citalopram actually blocks escitalopram’s serotonin-boosting activity in that setting.2PubMed Central. The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse Whether the R-enantiomer matters clinically remains debated, but the bottom line is that the two drugs share the same active ingredient; escitalopram just delivers it in a cleaner package.
How Their Effectiveness Compares
The most commonly asked question is whether escitalopram actually works better than citalopram. The answer depends on which studies you look at and how you define “better.” A meta-analysis pooling data from eight randomized controlled trials and about 2,000 patients found that escitalopram was statistically superior to citalopram on several measures. The estimated difference in depression scores at eight weeks was about 1.7 points on the MADRS scale, and the odds of achieving full remission were roughly 86% higher with escitalopram.3PubMed. Efficacy of escitalopram compared to citalopram: a meta-analysis A more recent systematic review confirmed the direction of that finding, showing escitalopram was more effective than citalopram for both response and remission in acute treatment of major depression.4PubMed Central. Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis
That said, not every trial tells the same story. A pooled analysis of three clinical trials found that the efficacy of citalopram at 20 to 40 mg per day was statistically equivalent to escitalopram at 10 to 20 mg per day over six weeks.5Annals of Clinical Psychiatry. Citalopram and Escitalopram in the Treatment of Major Depressive Disorder: A Pooled Analysis of 3 Clinical Trials A separate randomized trial of about 200 patients using flexible dosing likewise found no significant difference in depression scores, response rates, or remission rates between the two drugs.6PubMed. Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study
How do you reconcile these results? The meta-analyses that favor escitalopram carry more statistical weight because they combine larger patient pools. But the advantage they detect is modest. A difference of under two points on a depression rating scale may be statistically significant without being something most patients would notice in their daily lives. The remission advantage is more clinically meaningful: roughly six patients would need to be treated with escitalopram instead of citalopram for one additional person to achieve full remission.3PubMed. Efficacy of escitalopram compared to citalopram: a meta-analysis That is a real difference, but it’s not dramatic. For any individual person, the response to either drug will be shaped by their own biology more than by the average results of a clinical trial.
Dosing and How the Numbers Translate
Because escitalopram is the purified active component, it’s used at roughly half the milligram dose of citalopram. A standard starting dose of escitalopram is 10 mg, and for citalopram it’s 20 mg. Maximum recommended doses are 20 mg for escitalopram and 40 mg for citalopram, though the citalopram ceiling has been lowered to 20 mg in older adults due to heart-rhythm concerns.
If you’re switching from one to the other, the rough conversion is straightforward: 10 mg of escitalopram is comparable to 20 mg of citalopram, and 20 mg of escitalopram maps to 40 mg of citalopram. These equivalencies hold up in dose-equivalence research that compared antidepressant doses across randomized trials. The practical takeaway is that the lower milligram numbers on an escitalopram prescription don’t mean you’re getting a weaker drug. You’re getting the same active ingredient in a more concentrated form.
Side Effects
Both drugs share the same core side-effect profile you would expect from this drug class: nausea, headache, drowsiness, sexual dysfunction, and sleep disruption are the most frequently reported. In the head-to-head trials that compared the two drugs directly, most found no significant difference in the overall rate or severity of adverse effects.6PubMed. Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study This makes pharmacological sense: since escitalopram is the active half of citalopram, the side effects should largely overlap when given at equivalent doses.
Where the two drugs diverge slightly is on heart-rhythm safety. Both citalopram and escitalopram can cause a dose-dependent prolongation of the QT interval on an electrocardiogram, which in rare cases raises the risk of a dangerous heart-rhythm disturbance. Regulatory agencies imposed a ceiling dose of 40 mg per day for citalopram (20 mg for adults over 60) specifically because of this concern. Escitalopram carries a similar warning at higher doses but has generally been viewed as having a somewhat more favorable cardiac profile at standard doses. If you have a known heart condition or take other medications that affect the QT interval, this distinction might steer a prescriber toward one drug over the other or toward lower doses of either.
What Your Genes Have to Do With It
Both citalopram and escitalopram are broken down in the liver primarily by an enzyme called CYP2C19. People carry different versions of the gene for this enzyme, and those versions determine whether you metabolize the drug slowly, at a normal rate, or unusually fast. This matters because it directly affects how much active drug ends up circulating in your blood at any given dose.
A meta-analysis of pharmacogenetic studies found that people who are slow metabolizers of CYP2C19 had nearly double the drug exposure compared to normal metabolizers, while ultrarapid metabolizers cleared the drug about a third faster than normal.7PubMed. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis In practical terms, a slow metabolizer taking a standard dose could be experiencing the blood levels of someone taking a much higher dose, increasing the risk of side effects. A retrospective study confirmed this pattern: for each step up in CYP2C19 metabolizer activity, the odds of drug intolerability dropped by about 27%.8PubMed Central. Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study
Pharmacogenetic testing for CYP2C19 is increasingly available and can help guide dosing for both drugs. If you’ve struggled with side effects on one of these medications or found it ineffective at usual doses, genetic testing may explain why. Someone who is an ultrarapid metabolizer, for instance, might be clearing the drug so quickly that they never reach a therapeutic level, and would do better at a higher dose or on a different medication entirely. This enzyme variability applies equally to both citalopram and escitalopram, since they’re processed through the same pathway.
Drug Interactions
One of the reasons these two drugs remain popular is that they play well with other medications. Citalopram is metabolized by more than one liver enzyme pathway, and it has very little tendency to block any of those pathways for other drugs. In studies combining citalopram with substrates of the major liver enzymes, researchers observed no meaningful changes or only very small ones in the blood levels of the other drugs.9European Neuropsychopharmacology. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram Escitalopram has a similarly clean interaction profile; laboratory studies showed it has negligible inhibitory effects on the major liver enzymes and on a transport protein called P-glycoprotein.10PubMed. The clinical pharmacokinetics of escitalopram
The main interaction risk for both drugs isn’t pharmacokinetic (one drug altering the blood levels of another) but pharmacodynamic: combining either drug with another serotonin-raising agent creates a risk of serotonin syndrome, a potentially serious condition involving agitation, rapid heart rate, muscle rigidity, and fever. This risk exists with all SSRIs and applies equally to citalopram and escitalopram. The drugs to watch out for include MAO inhibitors, certain migraine medications (triptans), the pain reliever tramadol, and the supplement St. John’s wort.
Approved Uses and Off-Label Prescribing
Both drugs are FDA-approved for major depressive disorder. Citalopram received approval in 1998, and escitalopram followed in 2002. A key regulatory distinction is that escitalopram also carries an approval for generalized anxiety disorder, while citalopram does not.11Psychopharmacology Institute. What’s the Difference Between Citalopram and Escitalopram?
In practice, both drugs are prescribed for a range of anxiety-related conditions beyond their labeled indications, including panic disorder, social anxiety disorder, and obsessive-compulsive disorder. Citalopram’s lack of an anxiety-specific approval doesn’t mean it’s less effective for anxiety; it usually means the manufacturer didn’t seek that particular indication. Off-label prescribing is common and well-supported by clinical experience with both drugs.
Cost, Generics, and Prescribing Trends
When escitalopram was first released as the brand-name Lexapro, it was significantly more expensive than generic citalopram, and many viewed it with skepticism as a pharmaceutical strategy to extend patent life on what was essentially the same active ingredient. That dynamic has shifted substantially. Both drugs are now available as generics, and the cost difference between them has shrunk dramatically. An analysis of U.S. prescribing data found that brand-name versions of both drugs cost roughly 50 times more than their generic equivalents, but since most patients now receive generics, the out-of-pocket difference between citalopram and escitalopram is often negligible.12PubMed Central. Patterns in (es)citalopram prescriptions to Medicaid and Medicare patients in the United States: the potential effects of evergreening
Prescribing trends have shifted over time. Citalopram prescriptions have been declining while escitalopram prescriptions have been climbing, a pattern observed in both Medicare and Medicaid populations.13PubMed Central. Rise of escitalopram and the fall of citalopram This migration likely reflects a combination of the evidence favoring escitalopram’s slightly better efficacy, the cardiac dose-ceiling concerns for citalopram, and the disappearance of the cost barrier once escitalopram went generic. Whether the shift represents a genuine clinical improvement for patients at the population level, or is partly driven by marketing and prescribing inertia, is debated.
Older Adults and Sodium Levels
Older adults deserve special mention because both drugs carry a risk of hyponatremia, a drop in blood sodium levels that can cause confusion, falls, and in severe cases, seizures. A large retrospective study of patients newly started on citalopram found that about 16.5% developed hyponatremia. The risk increased with each additional year of age and was also higher in patients taking thiazide diuretics (a common blood-pressure medication) and, somewhat surprisingly, in men rather than women.14PubMed Central. Factors Associated with Hyponatremia in Patients Newly Prescribed Citalopram: A Retrospective Observational Study This risk applies to SSRIs as a class, not just citalopram, and there is no strong evidence that escitalopram is safer in this regard. For older patients starting either drug, checking sodium levels in the first few weeks is a reasonable precaution, especially if they take a diuretic.
The cardiac dose ceiling mentioned earlier also hits older adults harder. Since citalopram’s maximum recommended dose is 20 mg in people over 60, clinicians who want to push the dose higher for a patient who hasn’t fully responded are essentially blocked. Escitalopram offers a bit more room in that scenario, since its 20 mg ceiling is still available to older adults who tolerate it well.
Pregnancy and Breastfeeding
The safety data on both drugs during pregnancy is reassuring but imperfect, as it always is with medications used in pregnancy. A comprehensive review of escitalopram’s safety found that while some cases of major malformations were reported after first-trimester exposure, the rate of these events fell within the expected range seen in unexposed pregnancies. Exposure to escitalopram was associated with some pregnancy complications, but no adverse effects were reported in the small number of studies that evaluated breastfeeding.15PubMed. The safety of escitalopram during pregnancy and breastfeeding: a comprehensive review Citalopram has a longer track record in pregnancy research simply because it has been available longer, and the overall safety profile is similar. Neither drug is considered a first-tier risk during pregnancy, but the decision to continue, switch, or stop an antidepressant during pregnancy is always individualized. The risk of untreated depression during pregnancy is itself a serious concern, and for many patients the benefits of continuing treatment outweigh the potential risks.
Switching Between the Two
If your prescriber suggests switching from citalopram to escitalopram (or vice versa), the process is typically straightforward because the active molecule is the same. A common approach is a direct crossover: stop one and start the other the next day at the equivalent dose, without the gradual taper-and-titrate schedule you’d need when switching between chemically unrelated antidepressants. For example, someone on citalopram 20 mg would switch to escitalopram 10 mg. Some clinicians still prefer a brief overlap period, but discontinuation symptoms during the switch are uncommon precisely because you’re not withdrawing the active compound from your system.
Reasons people switch include wanting the potential efficacy edge of escitalopram, running into the citalopram dose ceiling due to cardiac concerns, or experiencing side effects at a given citalopram dose that they hope the lower milligram escitalopram dose might soften. Switching in the other direction, from escitalopram to citalopram, sometimes happens for insurance or formulary reasons when cost is a factor. Neither direction of switching carries unusual risks.
How Individual Response Varies More Than Drug Choice
The honest reality with these two medications is that the variation in how different people respond to the same drug dwarfs the average difference between the drugs themselves. Two people taking escitalopram 10 mg can have vastly different blood levels, different side-effect experiences, and different degrees of symptom relief, driven by their CYP2C19 genetics, their age, their other medications, and biological factors we don’t yet fully understand. The meta-analyses showing escitalopram’s statistical edge are describing averages across hundreds of patients, and within those averages lies enormous individual scatter.
If you’re currently doing well on citalopram, there is no compelling reason to switch to escitalopram. The modest average advantage in clinical trials does not mean escitalopram is universally better for every patient. Conversely, if you’ve tried citalopram without success, it’s worth knowing that escitalopram isn’t just a carbon copy, since the absence of the R-enantiomer and the different dosing may produce a different experience for you. And if neither drug works, the broader SSRI class and other antidepressant families offer many alternatives, which is where the conversation with your prescriber becomes more important than any head-to-head study.